Idorsia successfully completes the offering of CHF 600m convertible bonds by way of private placement

Niederer Kraft Frey advised Idorsia Ltd on the issuance and offering of CHF 600 million senior unsecured convertible bonds due 2028 convertible into shares of Idorsia by way of private placement.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialised in the discovery, development and commercialisation of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals, covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA) and has over 1,000 highly qualified specialists dedicated to realising its ambitious targets.

The net proceeds from the offering will be used to support commercial product launches in several key markets in 2022 (pending regulatory approval) and to fund the further development of the company’s advancing late-stage pipeline.

The NKF Team was led by Corporate and Capital Markets partner Philipp Haas, working with partner Daniel Bono and senior associate Julia Tolstova (both Corporate and Capital Markets).